ITCI
Intra-Cellular Therapies, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth -7.1% ·
share flow +1.9% ·
net new positions -7.7%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q1 2025 | 17 | +2 | 13.58M | $1.79B | +3 | −1 |
| Q4 2024 | 15 | +1 | 12.62M | $1.05B | +1 | — |
| Q3 2024 | 13 | -1 | 9.99M | $731.14M | +1 | −2 |
| Q2 2024 | 14 | — | 9.81M | $671.63M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Norges Bank ✦ (passive) | 3.20M | +64.6% | $234.05M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.71M | +1.3% | $125.03M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.71M | +1.3% | $125.03M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Marshall Wace ✦ | 1.16M | +132.7% | $84.95M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 1.04M | -27.0% | $76.28M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 1.04M | -27.0% | $76.28M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 1.02M | -18.8% | $74.46M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 1.02M | -18.8% | $74.46M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | Wellington Management ✦ | 1.02M | -18.8% | $74.46M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 1.02M | -18.8% | $74.46M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 1.02M | -18.8% | $74.46M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | Millennium Management ✦ | 499.30K | -43.8% | $36.53M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 461.83K | +338.0% | $33.79M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 461.83K | +338.0% | $33.79M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 461.83K | +338.0% | $33.79M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 368.68K | -36.5% | $26.98M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 368.68K | -36.5% | $26.98M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 18 | Renaissance Technologies ✦ | 196.20K | -11.8% | $14.36M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | Adage Capital Partners ✦ | 185.00K | -63.1% | $13.54M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 20 | Point72 Asset Management ✦ | 119.86K | -78.4% | $8.77M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 21 | Two Sigma Investments ✦ | 23.49K | New | $1.72M | 0.0% | New | 1 | SEC ↗ |
| 22 | Gotham Asset Management ✦ | 9.51K | +79.8% | $695,554 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Two Sigma Investments | $1.72M | 0.0% |
Exited
| Citadel Advisors | $9.16M | was 0.0% |
| Arrowstreet Capital | $268,000 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 1 shares, $2,540 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.